Trial Profile
Randomised, prospective study of ablative fractional laser-assisted photodynamic therapy using methyl aminolevulinate (MAL) as an effective first-line treatment for actinic keratosis (AK).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Methyl aminolevulinate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- 14 May 2016 New trial record